Polaryx Therapeutics (PLYX)
Develops PLX-200 and other candidates for rare pediatric lysosomal storage disorders.
$2.02
Pre-market−0.01 (−0.49%)
At close$2.03(+2.53%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions14 holders · as of Mar 31, 2026 | 4.55% | 2.27M shares | |
| Otherremainder | 95.45% | 47.58M shares |
49.85M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Institutions13F, as of Mar 31, 2026
14 holders · 2.27M shares · 14 new positions · 14 increased · 0 reduced · 0 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 1.66M | 3.33% | +1.66Mnew | May 15, 2026 |
| Geode Capital Management, LLC | 170.7K | 0.34% | +170.7Knew | May 15, 2026 |
| Millennium Management LLC | 127.5K | 0.26% | +127.5Knew | May 15, 2026 |
| Vanguard Fiduciary Trust Co | 104.6K | 0.21% | +104.6Knew | May 8, 2026 |
| State Street Corp | 58.1K | 0.12% | +58.1Knew | May 15, 2026 |
| BlackRock, Inc. | 41.0K | 0.08% | +41.0Knew | May 13, 2026 |
| Northern Trust Corp | 28.0K | 0.06% | +28.0Knew | May 14, 2026 |
| Bank of America Corp /DE/ | 25.9K | 0.05% | +25.9Knew | May 18, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.